Roy M. Pollock

11.6k total citations · 5 hit papers
55 papers, 6.4k citations indexed

About

Roy M. Pollock is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Roy M. Pollock has authored 55 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Molecular Biology, 22 papers in Hematology and 6 papers in Oncology. Recurrent topics in Roy M. Pollock's work include Epigenetics and DNA Methylation (23 papers), Cancer-related gene regulation (21 papers) and Acute Myeloid Leukemia Research (15 papers). Roy M. Pollock is often cited by papers focused on Epigenetics and DNA Methylation (23 papers), Cancer-related gene regulation (21 papers) and Acute Myeloid Leukemia Research (15 papers). Roy M. Pollock collaborates with scholars based in United States, United Kingdom and Canada. Roy M. Pollock's co-authors include Richard Treisman, Victoria M. Richon, M J Runswick, Christine M. Norman, Robert A. Copeland, Margaret Porter Scott, Kevin W. Kuntz, Tim Clackson, Sarah K. Knutson and Mikel P. Moyer and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Roy M. Pollock

55 papers receiving 6.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Isolation and properties of cDNA clones encoding SRF, a transcription factor that binds to the c-fos serum response element

1988 880 citations Christine M. Norman, M J Runswick et al. Cell profile →
MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L

2011 642 citations Kathrin M. Bernt, Nan Zhu et al. Cancer Cell profile →
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

2013 581 citations Sarah K. Knutson, Natalie M. Warholic et al. Proceedings of the National Academy of Sciences profile →
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

2013 546 citations Scott R. Daigle, Edward J. Olhava et al. Blood profile →
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas

2010 500 citations Christopher J. Sneeringer, Margaret Porter Scott et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roy M. Pollock United States	29	5.4k	958	748	636	385	55	6.4k
Junwei Shi United States	35	6.2k 1.1×	1.5k 1.5×	436 0.6×	1.3k 2.1×	513 1.3×	105	7.3k
Robert J. Sims United States	27	5.6k 1.0×	731 0.8×	438 0.6×	736 1.2×	311 0.8×	50	6.1k
Beric R. Henderson Australia	40	4.1k 0.7×	588 0.6×	764 1.0×	753 1.2×	206 0.5×	90	5.1k
Xiaobing Shi United States	48	7.1k 1.3×	325 0.3×	573 0.8×	868 1.4×	389 1.0×	104	8.2k
Nancy J. Zeleznik‐Le United States	32	3.2k 0.6×	1.3k 1.4×	335 0.4×	460 0.7×	559 1.5×	68	4.2k
Kurtis E. Bachman United States	30	6.5k 1.2×	435 0.5×	1.1k 1.5×	1.4k 2.1×	509 1.3×	51	7.6k
Ciaran G. Morrison Ireland	35	5.5k 1.0×	396 0.4×	815 1.1×	1.9k 3.0×	418 1.1×	87	6.4k
Alexei F. Kisselev United States	35	5.7k 1.0×	505 0.5×	489 0.7×	2.2k 3.5×	594 1.5×	57	6.4k
A Tavitian France	40	4.6k 0.8×	462 0.5×	552 0.7×	702 1.1×	781 2.0×	106	6.2k
W. Todd Miller United States	40	4.1k 0.7×	1.4k 1.5×	500 0.7×	1.4k 2.2×	543 1.4×	124	6.5k

Countries citing papers authored by Roy M. Pollock

Since Specialization

Citations

This map shows the geographic impact of Roy M. Pollock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roy M. Pollock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roy M. Pollock more than expected).

Fields of papers citing papers by Roy M. Pollock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roy M. Pollock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roy M. Pollock. The network helps show where Roy M. Pollock may publish in the future.

Co-authorship network of co-authors of Roy M. Pollock

This figure shows the co-authorship network connecting the top 25 collaborators of Roy M. Pollock. A scholar is included among the top collaborators of Roy M. Pollock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roy M. Pollock. Roy M. Pollock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Thomenius, Michael J., Jason K. Kirby, Roman V. Agafonov, et al.. (2023). CFT7455, a novel IKZF1/3 degrader, demonstrates potent activity in peripheral and CNS models of NHL as a single agent or in combination with clinically approved agents. Hematological Oncology. 41(S2). 550–551. 4 indexed citations

Agafonov, Roman V., Prasoon Chaturvedi, Scott J. Eron, et al.. (2022). CFT7455, a Novel IKZF1/3 Degrader, Demonstrates Potent Anti-Tumor Activity in Models of Non-Hodgkin's Lymphoma As a Single Agent or in Combination with Clinically Approved Agents. Blood. 140(Supplement 1). 11575–11575. 1 indexed citations

Campbell, Carly, David A. Drubin, Timothy M. Thomson, et al.. (2017). Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL -Rearranged Leukemia. Molecular Cancer Therapeutics. 16(8). 1669–1679. 46 indexed citations

Kawano, Satoshi, Alexandra Grassian, Masumi Tsuda, et al.. (2016). Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma. PLoS ONE. 11(7). e0158888–e0158888. 58 indexed citations

Waters, Nigel J., Sherri Smith, Edward J. Olhava, et al.. (2015). Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human. Cancer Chemotherapy and Pharmacology. 77(1). 43–62. 23 indexed citations

Klaus, Christine R., Danielle Johnston, J. Joshua Smith, et al.. (2014). DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs and Hypomethylating Agents in MLL-Rearranged Leukemia Cells. Journal of Pharmacology and Experimental Therapeutics. 350(3). 646–656. 96 indexed citations

Knutson, Sarah K., Natalie M. Warholic, L. Danielle Johnston, et al.. (2014). Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas. PLoS ONE. 9(12). e111840–e111840. 55 indexed citations

Daigle, Scott R., Edward J. Olhava, Aravind Basavapathruni, et al.. (2013). Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 122(6). 1017–1025. 546 indexed citations breakdown →

Basavapathruni, Aravind, Lei Jin, Scott R. Daigle, et al.. (2012). Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L. Chemical Biology & Drug Design. 80(6). 971–980. 114 indexed citations

10.

Chen, Liang, Anagha Deshpande, Deepti Banka, et al.. (2012). Abrogation of MLL–AF10 and CALM–AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia. 27(4). 813–822. 101 indexed citations

11.

Rivera, Victor M., Rachel M. Squillace, David F. Miller, et al.. (2011). Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens. Molecular Cancer Therapeutics. 10(6). 1059–1071. 87 indexed citations

12.

Bernt, Kathrin M., Nan Zhu, Amit Sinha, et al.. (2011). MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L. Cancer Cell. 20(1). 66–78. 642 indexed citations breakdown →

13.

Sneeringer, Christopher J., Margaret Porter Scott, Kevin W. Kuntz, et al.. (2010). Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proceedings of the National Academy of Sciences. 107(49). 20980–20985. 500 indexed citations breakdown →

14.

Pollock, Roy M. & Tim Clackson. (2002). Dimerizer-regulated gene expression. Current Opinion in Biotechnology. 13(5). 459–467. 82 indexed citations

15.

Rebar, Alan H., et al.. (2001). A Guide to Hematology in Dogs and Cats. 8 indexed citations

16.

Pollock, Roy M. & Victor M. Rivera. (1999). [15] Regulation of gene expression with synthetic dimerizers. Methods in enzymology on CD-ROM/Methods in enzymology. 306. 263–281. 13 indexed citations

17.

Rivera, Victor M., Tim Clackson, Sridaran Natesan, et al.. (1996). A humanized system for pharmacologic control of gene expression. Nature Medicine. 2(9). 1028–1032. 433 indexed citations

18.

Pollock, Roy M. & Richard Treisman. (1990). A sensitive method for the determination of protein-DNA binding specificities. Nucleic Acids Research. 18(21). 6197–6204. 308 indexed citations

19.

Norman, Christine M., M J Runswick, Roy M. Pollock, & Richard Treisman. (1988). Isolation and properties of cDNA clones encoding SRF, a transcription factor that binds to the c-fos serum response element. Cell. 55(6). 989–1003. 880 indexed citations breakdown →

20.

Pollock, Roy M., et al.. (1988). Identification and purification of EBP1: a HeLa cell protein that binds to a region overlapping the 'core' of the SV40 enhancer.. Genes & Development. 2(8). 991–1002. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact